Genialis

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world's most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

Biotechnology Boston, United States ~10 employees Private · Series A

Work at Genialis in HR or recruiting? Claim this page

Employees
10
0% in the 3 months to Sep 2026
Revenue / employee
$600K
Revenue ~$6M
Total funding
$15.3M
Last round Series A, Jan 2023
12-month attrition
25.5%
Tech: 360%
H1B filings, FY2024
1
Sponsors visas

Headcount trend

Genialis went from 10 employees in Oct 2024 to 10 in Sep 2026. Apr to Sep 2026: 3 people joined, 2 left.

Org structure

Headcount by department

Other7
Operations2
Sales1

Funding

  • Jan 2023 · Series A · $13M · Taiwania Capital, First Star Ventures, Redalpine Venture Partners
  • Nov 2017 · Seed · $2.3M · Redalpine Venture Capital, First Star Ventures

H-1B sponsorship

H-1B Sponsorship Limited
H-1B Filings by Department
Engineering1

Peer reviews

Worked with someone at Genialis?

Anonymous peer reviews on OffTheRecord

Read or write a review

Similar companies

Genialis FAQ

How many employees does Genialis have?

Genialis has about 10 employees, unchanged over the 3 months to Sep 2026.

Does Genialis sponsor H1B visas?

Yes. Genialis filed 1 H1B (LCA) application in FY2024, according to the latest U.S. Department of Labor disclosures. It was for a Engineering role.

What is Genialis's revenue per employee?

Genialis makes about $600K in revenue per employee, based on $6M annual revenue and 10 employees.

How much funding has Genialis raised?

Genialis has raised $15.3M in total funding; its latest round was Series A in Jan 2023.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.